Health Canada approves Adcetris (brentuximab vedotin) for the post-ASCT consolidation treatment of patients with Hodgkin lymphoma at increased risk of relapse or progression

25 July 2017 - Approval based on positive phase 3 AETHERA clinical trial results. ...

Read more →